DE60211199D1 - 3-substituierte oxindol-beta-3-agonisten - Google Patents
3-substituierte oxindol-beta-3-agonistenInfo
- Publication number
- DE60211199D1 DE60211199D1 DE60211199T DE60211199T DE60211199D1 DE 60211199 D1 DE60211199 D1 DE 60211199D1 DE 60211199 T DE60211199 T DE 60211199T DE 60211199 T DE60211199 T DE 60211199T DE 60211199 D1 DE60211199 D1 DE 60211199D1
- Authority
- DE
- Germany
- Prior art keywords
- agonists
- beta
- oxindol
- substituted
- substituted oxindol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31213501P | 2001-08-14 | 2001-08-14 | |
US312135P | 2001-08-14 | ||
PCT/US2002/021316 WO2003016276A2 (en) | 2001-08-14 | 2002-08-06 | 3-substituted oxindole beta-3 agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60211199D1 true DE60211199D1 (de) | 2006-06-08 |
DE60211199T2 DE60211199T2 (de) | 2007-02-01 |
Family
ID=23210032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60211199T Expired - Fee Related DE60211199T2 (de) | 2001-08-14 | 2002-08-06 | 3-substituierte oxindol-beta-3-agonisten |
Country Status (8)
Country | Link |
---|---|
US (2) | US6911463B2 (de) |
EP (1) | EP1444224B1 (de) |
JP (1) | JP2005507872A (de) |
AT (1) | ATE325119T1 (de) |
AU (1) | AU2002318206A1 (de) |
DE (1) | DE60211199T2 (de) |
ES (1) | ES2262817T3 (de) |
WO (1) | WO2003016276A2 (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2272749T3 (es) * | 2001-08-14 | 2007-05-01 | Eli Lilly And Company | Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2. |
WO2003044016A1 (en) * | 2001-11-20 | 2003-05-30 | Eli Lilly And Company | 3-SUBSTITUTED OXINDOLE β3 AGONISTS |
EP1448561B1 (de) | 2001-11-20 | 2008-02-20 | Eli Lilly And Company | Beta-3 adrenergische agonisten |
JP2005520805A (ja) | 2002-01-11 | 2005-07-14 | イーライ・リリー・アンド・カンパニー | 2−オキソ−ベンズイミダゾリル置換型エタノールアミン誘導体およびβ3アゴニストとしてのその使用 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
MX2007013179A (es) * | 2005-04-22 | 2008-01-16 | Wyeth Corp | Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina. |
BRPI0719210A2 (pt) * | 2006-10-12 | 2015-05-05 | Xenon Pharmaceuticals Inc | Uso de compostos espiro-oxindol como agentes terapêuticos |
CL2007002953A1 (es) * | 2006-10-12 | 2008-02-01 | Xenon Pharmaceuticals Inc | Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia. |
US20110237567A9 (en) * | 2006-10-12 | 2011-09-29 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2170930B3 (de) | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US8101647B2 (en) * | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
CA2741029A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
WO2011047173A2 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
EP2488531B1 (de) | 2009-10-14 | 2014-03-26 | Xenon Pharmaceuticals Inc. | Verfahren zur herstellung von spiro-oxindol derivaten |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP3266444A1 (de) | 2010-02-26 | 2018-01-10 | Xenon Pharmaceuticals Inc. | Pharmazeutische zusammensetzungen einer spirooxindolverbindung zur topischen verabreichung und deren verwendung als therapeutika |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
PE20140859A1 (es) | 2011-02-25 | 2014-07-25 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
EP2958562A4 (de) | 2013-02-22 | 2016-08-10 | Merck Sharp & Dohme | Antidiabetische bicyclische verbindungen |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP3004138B1 (de) | 2013-06-05 | 2024-03-13 | Bausch Health Ireland Limited | Ultrareine agonisten von guanylatcyclase c, verfahren zur herstellung und verwendung davon |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
EP3551176A4 (de) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetische heterocyclische verbindungen |
EP3558298A4 (de) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Antidiabetische spirochromanverbindungen |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB159945A (en) | 1919-11-28 | 1921-02-28 | Ernest Henry Jones | Removable covers for welding and like furnaces |
CH624395A5 (de) | 1976-01-08 | 1981-07-31 | Ciba Geigy Ag | |
CA1116598A (en) | 1977-07-13 | 1982-01-19 | William T. Comer | 3-indolyl-tertiary butylaminopropanols |
JPS6010021B2 (ja) | 1979-01-31 | 1985-03-14 | 田辺製薬株式会社 | 新規ベンジルアルコ−ル誘導体及びその製法 |
DE3423429A1 (de) | 1984-06-26 | 1986-01-02 | Beiersdorf Ag, 2000 Hamburg | Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen |
DE3426419A1 (de) | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
US4728651A (en) | 1985-10-24 | 1988-03-01 | Hoechst-Roussel Pharmaceuticals Inc. | Antihypertensive thieno-isoxazoles and -pyrazoles |
GB8528633D0 (en) | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
NO303782B1 (no) | 1994-03-23 | 1998-08-31 | Sankyo Co | Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter |
IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
US6075040A (en) | 1996-09-05 | 2000-06-13 | Eli Lilly And Company | Selective β3 adrenergic agonists |
ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
ATE215369T1 (de) | 1996-09-05 | 2002-04-15 | Lilly Co Eli | Carbazolanaloge als selektive beta3-adrenergische agonisten |
BR9807096A (pt) | 1997-01-28 | 2000-04-18 | Merck & Co Inc | Composto, processos para o tratamento do diabetes, da obesidade em um mamìfero, para reduzir nìveis de triglicerìdeos e nìveis de colesterol ou elevar nìveis de lipoproteìnas de alta densidade, para diminuir a motilidade do intestino, para reduzir inflamação neurogênica das vias aéreas e a depressão e para tratar distúrbios gastrintestinais, e, composições para o tratamento dos distúrbios acima e farmacêutica |
US6011048A (en) | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
AUPP796798A0 (en) | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
JP2003055344A (ja) | 1999-01-29 | 2003-02-26 | Dainippon Pharmaceut Co Ltd | 3,7−ジ置換インドール誘導体及びそれを含有する医薬組成物 |
AU6050000A (en) | 1999-07-22 | 2001-02-13 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
AU1572701A (en) | 1999-11-15 | 2001-05-30 | Eli Lilly And Company | Treating wasting syndromes with aryloxy propanolamines |
AU1580001A (en) | 1999-11-15 | 2001-05-30 | Eli Lilly And Company | Process for the preparation of aryloxy propanolamines |
AU2001236471A1 (en) | 2000-01-18 | 2001-07-31 | Neurogen Corporation | Imidazopyridines and related azacyclic derivatives as selective modulators of bradykinin b2 receptors |
CN1441800A (zh) | 2000-07-13 | 2003-09-10 | 伊莱利利公司 | β3肾上腺素能激动剂 |
US6825220B2 (en) * | 2000-11-10 | 2004-11-30 | Eli Lilly And Company | 3-Substituted oxindole β 3 agonists |
-
2002
- 2002-08-06 ES ES02748081T patent/ES2262817T3/es not_active Expired - Lifetime
- 2002-08-06 DE DE60211199T patent/DE60211199T2/de not_active Expired - Fee Related
- 2002-08-06 EP EP02748081A patent/EP1444224B1/de not_active Expired - Lifetime
- 2002-08-06 AT AT02748081T patent/ATE325119T1/de not_active IP Right Cessation
- 2002-08-06 US US10/486,508 patent/US6911463B2/en not_active Expired - Fee Related
- 2002-08-06 AU AU2002318206A patent/AU2002318206A1/en not_active Abandoned
- 2002-08-06 JP JP2003521203A patent/JP2005507872A/ja active Pending
- 2002-08-06 WO PCT/US2002/021316 patent/WO2003016276A2/en active IP Right Grant
-
2005
- 2005-03-16 US US11/082,106 patent/US7087635B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE325119T1 (de) | 2006-06-15 |
JP2005507872A (ja) | 2005-03-24 |
WO2003016276A3 (en) | 2004-05-27 |
DE60211199T2 (de) | 2007-02-01 |
EP1444224B1 (de) | 2006-05-03 |
US6911463B2 (en) | 2005-06-28 |
US20040242668A1 (en) | 2004-12-02 |
AU2002318206A1 (en) | 2003-03-03 |
ES2262817T3 (es) | 2006-12-01 |
US20050159473A1 (en) | 2005-07-21 |
WO2003016276A2 (en) | 2003-02-27 |
US7087635B2 (en) | 2006-08-08 |
EP1444224A2 (de) | 2004-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60211199D1 (de) | 3-substituierte oxindol-beta-3-agonisten | |
ATE340794T1 (de) | Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes | |
ATE329901T1 (de) | 3-substituierte oxindolderivate als beta-3- agonisten | |
DE60204718D1 (de) | 3-substituierte oxindol beta 3 agonisten | |
BRPI0418149A (pt) | derivados heterocìclicos como agonistas do receptor de gprc | |
DE602004012858D1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
DK1204654T3 (da) | Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister | |
BR0112582A (pt) | Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos | |
ATE470662T1 (de) | Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor | |
DK0957099T3 (da) | Heterocykliske carboxamider | |
NO20080052L (no) | G-Protein kopplede reseptoragonister | |
DE60135485D1 (de) | Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa | |
MY134568A (en) | Cb2 receptor agonists | |
GB0223038D0 (en) | Therapeutic compounds | |
BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
EA200300717A1 (ru) | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов | |
BR0317819A (pt) | Aparelho para acesso restrito do navegador dentro de um dispositivo de comunicação sem fio e método para o mesmo | |
DK1109817T3 (da) | Phosphohalogenhydriner, deres fremstilling og anvendelse | |
DE602004006869D1 (de) | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit | |
DK1392643T3 (da) | (1S)-1,2,3,4-tetrahydro-1-naphthalenylbenzamider, der er trisubstituerede ved N, og som inhiberer receptorer indeholdende P2X3 og P2X2/3 | |
EA200701676A1 (ru) | Производные дигидроимидазотиазола | |
BR9901058A (pt) | N-cail e n-aroil aralquil amidas. | |
NO984047D0 (no) | Nye svovelderivater omfattende en amidbinding, metode for fremstilling av disse, anvendelse derav som legemidler og farmas°ytiske preparater inneholdende slike derivater | |
ATE460938T1 (de) | Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion | |
BR0214886A (pt) | Fenilalquinos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
8339 | Ceased/non-payment of the annual fee |